IBJNews

Lilly: Vendors key after Zyprexa patent loss

Back to TopCommentsE-mailPrintBookmark and Share

Today’s the day. At the start of business this morning, Eli Lilly and Co. no longer had U.S. patent protection on its best-selling drug, Zyprexa, a loss that threatens to open a gaping hole in the finances of the locally based drugmaker.

The Indianapolis area and even the state of Indiana hope Lilly’s challenges don’t create similar holes in Hoosiers’ incomes.

That’s because Lilly’s 11,500 employees in Indiana receive average compensation of $151,000 per year—more than double the state average. And their earnings help stoke numerous service businesses, from retailers to restaurants to real estate agents and wealth advisers.

On top of that, Lilly contracts with 1,300 vendors in Indiana, spending nearly $1.1 billion every year for their goods and services. Those range from high-end scientific and manufacturing work, to legal and accounting help, to janitorial and food services.

The majority of that money is spent in Indianapolis and its nearby counties, according to a breakdown on Lilly’s website. But Lilly has at least one vendor in 59 of Indiana’s 92 counties.

“Our footprint is pretty far and wide in the state of Indiana,” said Mike O’Connor, Lilly’s director of state government affairs.

In Marion County, Lilly spent $639 million with 675 vendors last year. In Hamilton County, the drugmaker shelled out $71 million to 187 vendors. And in Hancock County, where Lilly has its animal-health subsidiary headquartered and also contracts with laboratories operated by New Jersey-based Covance Inc., it spent $70 million with 47 vendors.

Some of this spending used to be done entirely under Lilly’s umbrella. But Lilly agreed to sell its Hancock County labs in 2008 to Covance, and transferred 280 employees to the new owner.

Similarly in 2009, Lilly agreed to sell its Tippecanoe County manufacturing plant to Germany-based Evonik Industries AG. Now Tippecanoe County receives the second-largest amount of Lilly’s largesse, totaling $195 million to 115 vendors last year.

Trying to overcome the loss of revenue from the $5 billion-a-year antipsychotic Zyprexa, which also lost its European patent in the past month, requires Lilly to rely on its vendors more than ever, O’Connor said.

Lilly also faces the loss of revenue from its No. 2-selling drug, the antidepressant Cymbalta, in 2013. Cymbalta is on pace this year for $4 billion in sales.

“The business climate is going to require us to develop more partnerships,” O’Connor said, adding, “Our vendor network has to be included in our business strategy, more so than it’s ever been.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT